Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197)

Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197)

PB-119 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
PB-119
Population
t2d
Phase
3
Participants
310
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
150 μg QWt2d china24310——−1.2 vs −0.7—7.4 vs 7.74.2 vs 0.34.8 vs 0.32.9 vs 3.9—press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (5)
  • 150 μg QW · hba1c · publication
    was −1.25% (95% confidence interval (CI), −1.35 to −1.16) in the visepegenatide group and −0.68% (95% CI, −0.78 to −0.59) in the placebo group.
  • 150 μg QW · disc_any · Results, first paragraph
    During the 24-week double-blind period, 287 (92.6%) participants in the visepegenatide group and 286 (92.2%) participants in the placebo group completed the treatment and entered the extension phase.
  • 150 μg QW · nausea · Table 3, double-blind columns (Visepegenatide N=310, Placebo
    Nausea 13 (4.2) 31 1 (0.3)
  • 150 μg QW · sae · Table 3, double-blind columns
    Serious adverse events (SAEs) 9 (2.9) 10 12 (3.9)
  • 150 μg QW · vomiting · Table 3, double-blind columns
    Vomiting 15 (4.8) 30 1 (0.3)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-add-on-to-metformin/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.